BOC Sciences provides precise, data-driven excipient screening services that help formulation scientists select compatible, functional, and stable excipients early in development. We combine drug-excipient compatibility testing, physical and chemical characterization, stress screening, and application-oriented evaluation so that clients can build a rational excipient matrix. Every project is tailored to the API's chemistry, the target dosage form, and the client's development stage, with clear ranking and recommendations at the end.
Excipient screening is the systematic evaluation of pharmaceutical ingredients to identify which ones are chemically and physically compatible with the active pharmaceutical ingredient (API), support the intended function of the formulation, and remain stable under processing and storage conditions. It goes beyond simple mixing tests: it assesses drug-excipient interactions, moisture sensitivity, oxidation risk, pH effects, mechanical behavior, and solubility performance. A well-designed screening reduces downstream surprises in content, stability, dissolution, and manufacturability, and it is especially valuable when API material is limited and decisions must be made quickly and confidently.
BOC Sciences screens solubilizers and co-solvent systems to improve the apparent solubility and dissolution of poorly water-soluble APIs.
We screen buffer systems and pH modifiers to stabilize the API in its optimal ionization state and avoid pH-driven degradation.
BOC Sciences evaluates surfactants and wetting agents to improve wettability, dispersion, and dissolution of hydrophobic surfaces.
Our team screens stabilizers, antioxidants, and chelating agents to protect APIs against oxidation, metal-catalyzed degradation, and aggregation.
BOC Sciences screens fillers, binders, and disintegrants for tablet and capsule development to balance compaction, flow, and disintegration.
We evaluate lubricants, glidants, and processing aids to improve powder flow, reduce sticking, and protect formulation quality during tableting.
Our polymer screening supports modified-release and film-coating development by tuning release kinetics and mechanical robustness.
BOC Sciences screens cryoprotectants, lyoprotectants, and bulking agents to stabilize molecules during freeze-drying and frozen storage.
BOC Sciences helps research teams move from API chemistry and target dosage form to a structured excipient matrix, compatibility testing, functional ranking, formulation confirmation, and a clear recommendation report.
BOC Sciences adapts screening depth, excipient panels, stress conditions, and analytical endpoints to the molecule, formulation type, available material, and decision required. Representative project categories include:
| Project Type | Screening Focus and Key Outputs |
| Small-Molecule APIs | Binary and multicomponent screening for chemical compatibility, moisture sensitivity, oxidation, solid-state change, solubility, precipitation, dissolution, and excipient concentration effects. |
| Peptides and Proteins | Evaluation of buffers, sugars, polyols, amino acids, surfactants, antioxidants, and chelators for aggregation control, particle reduction, structural retention, and recovery after stress. |
| Oral Solid Formulations | Selection of fillers, binders, disintegrants, lubricants, glidants, surfactants, and release modifiers based on compatibility, powder behavior, compaction, disintegration, and dissolution. |
| Liquid Formulations | Screening of buffers, co-solvents, complexing agents, surfactants, tonicity modifiers, stabilizers, and antioxidants for clarity, solubility, precipitation resistance, viscosity, and chemical stability. |
| Suspensions and Emulsions | Comparison of wetting agents, surfactants, polymers, viscosity modifiers, and density-adjusting excipients for particle size, redispersibility, creaming, sedimentation, phase stability, and drug recovery. |
| Semisolid Formulations | Assessment of solvents, emollients, gelling agents, humectants, penetration modifiers, surfactants, and antioxidants for API distribution, rheology, phase behavior, and stress stability. |
| Lyophilized Formulations | Selection of cryoprotectants, lyoprotectants, bulking agents, buffers, and surfactants based on freeze-thaw recovery, thermal behavior, cake structure, residual moisture, and reconstitution. |
| Excipient Replacement Studies | Comparison of alternative grades or functional substitutes when an existing excipient causes instability, poor processing, supply constraints, analytical interference, or inconsistent product performance. |
Share your API structure, solubility, stability sensitivities, target dosage form, and current formulation problem. Our specialists will design a project-specific plan covering candidate selection, compatibility analysis, functional testing, analytical confirmation, and a clear excipient recommendation report.
BOC Sciences reviews the API chemistry, target dosage form, development stage, and stability concerns, then selects a focused panel of candidate excipients with the right functionality and compatibility profile.
Our team performs binary and prototype blend studies under controlled stress, combining thermal, spectroscopic, chromatographic, and mass spectrometric methods to rank excipients by compatibility and function.
Screened excipients are blended into prototype formulations and evaluated for disintegration, dissolution, flow, compaction, and stability so that the most promising matrix is confirmed with data.
Clients receive a ranked excipient matrix, analytical data, formulation recommendations, and full project records for confident downstream development and future scale-up decisions.
A chemically incompatible excipient can silently accelerate degradation, reduce assay, or change solid form without obvious signs in routine testing. BOC Sciences uses a combination of thermal, spectroscopic, and chromatographic methods to expose interactions that a single analytical technique would miss. We rank excipients by risk, distinguish physical mixtures from true reactions, and recommend the safest compatible panel before formulation effort is committed.
Many APIs degrade through hydrolysis or oxidation triggered by water, trace metals, or reactive excipients. BOC Sciences identifies the moisture and oxidation sensitivity of the API, then screens stabilizers, antioxidants, chelators, and low-moisture excipients under controlled humidity and oxygen exposure. We quantify degradation by LC-based methods, giving clients a clear protection strategy for the formulation.
Excipients can interfere with analytical signals, producing apparent degradation or masking real changes in content and purity. BOC Sciences designs screening methods with excipient interference in mind, using appropriate sample preparation, gradient separation, and analytical method optimization. Orthogonal confirmation by multiple techniques helps separate true incompatibility from artifacts, so clients trust the screening conclusions.
Poorly soluble APIs often need a combination of solubilizers, surfactants, polymers, and solid-state strategies, but too many options create confusion. BOC Sciences screens solubilizers, co-solvents, surfactants, and amorphous-stabilizing polymers side by side, then confirms the best combination at the formulation level. This reduces the risk of precipitation, poor bioavailability, and wasted API material in early development.
Share your API properties, formulation challenges, candidate excipients, observed instability, and project requirements with our experts. BOC Sciences can help identify potential interaction risks, design a focused screening plan, compare suitable excipient options, and translate the results into practical formulation recommendations.
BOC Sciences combines API understanding, excipient chemistry, and orthogonal analytical testing in a single workflow. This helps clients avoid fragmented screening, inconsistent data, and conflicting conclusions, and supports better decisions when solubility, stability, and manufacturability must be considered together.
We do not apply a fixed excipient kit to every project. Our scientists select candidates based on the API's chemistry, the target dosage form, and the intended function of each excipient. This application-first approach increases the chance of identifying a compatible, functional matrix that works in the client's real formulation.
A single assay can miss important interactions. Our analytical platform combines thermal, spectroscopic, chromatographic, and mass spectrometric methods to confirm findings across techniques. This gives clients clear evidence for ranking excipients and choosing a stable, functional formulation.
From early preformulation to solid oral, liquid, semisolid, and injectable systems, BOC Sciences adapts the screening workflow to the dosage form and development stage. We also support related services such as salt form screening and micronization to address solubility and solid-state challenges holistically.
Client Needs: A formulation team needed to select fillers, binders, and disintegrants for a moisture-sensitive weak-base API intended for an immediate-release tablet. Only limited API material was available, and an early blend had shown assay loss after warm, humid storage.
Challenges: Thermal screening produced several peak shifts, but it was unclear whether they represented degradation, melting-point depression, or simple mixing effects. The API also showed pH-dependent dissolution, making it necessary to evaluate compatibility and release performance together.
Solution: We prepared neat-API controls and binary blends with eight candidate excipients at application-relevant and challenge ratios. Samples were stressed under dry and moisture-added conditions, then examined by DSC, XRD, HPLC, and LC-MS. Chromatographic changes were compared with thermal events to separate true degradation from physical mixing effects. Two excipients were excluded, and three compatible combinations advanced to dissolution testing.
Outcome: The team received a ranked excipient matrix, evidence supporting the removal of two high-risk candidates, and three formulation combinations with improved assay recovery and suitable immediate-release behavior for further optimization.
Client Needs: A biotechnology group required a liquid formulation for a recombinant protein that formed visible particles after agitation and showed increasing soluble aggregates during short thermal stress. The team wanted a compact stabilizer screen that conserved protein material.
Challenges: Buffer species, surfactant concentration, and sugar type affected different failure modes. Some conditions reduced turbidity but increased soluble aggregates, while others protected against agitation but caused pH drift after freeze-thaw cycling.
Solution: We screened four buffers, three nonionic surfactants, three sugars or polyols, and two amino-acid stabilizers in a 24-condition microscale matrix. Turbidity, particle size, SEC-HPLC, and LC-MS were measured before and after agitation, freeze-thaw, and short thermal stress. A buffer-sugar-surfactant combination reduced soluble aggregate formation and visible particles while maintaining concentration and acceptable pH after stress.
Outcome: The client received a multi-attribute ranking of the 24 conditions and a focused formulation window for confirmatory concentration optimization and extended stability assessment.
Excipients do not provide the primary pharmacological effect, but they can influence an API through moisture, peroxides, aldehydes, trace metals, microenvironmental pH, adsorption, or solid-state interactions. These effects may cause degradation, crystal-form conversion, solubility changes, precipitation, aggregation, or altered drug release. Compatibility studies identify such risks before extensive formulation optimization, distinguish chemical reactions from ordinary physical mixing effects, and provide evidence for excluding unsuitable excipients. The findings can also guide material replacement, concentration adjustment, protective additive selection, and the design of more stable excipient combinations.
Drug-excipient compatibility is commonly evaluated by comparing neat API controls, neat excipient controls, binary mixtures, and selected multicomponent formulations. Samples may be exposed to dry, moisture-added, thermal, light, oxidative, or solution stresses selected for the expected degradation pathway. DSC, TGA, XRD, FTIR, Raman, HPLC, and LC-MS can then evaluate thermal events, solid-form changes, molecular interactions, API recovery, and degradant formation. Important signals should be confirmed with orthogonal methods because melting-point depression, physical mixing, incomplete extraction, excipient peaks, or ion suppression may otherwise be misinterpreted as genuine incompatibility.
Screening for a poorly soluble drug may include pH modifiers, buffers, co-solvents, surfactants, cyclodextrins, hydrophilic polymers, precipitation inhibitors, complexing agents, and lipid-based excipients. The appropriate panel depends on ionization behavior, crystal form, lipophilicity, target drug loading, processing route, and intended dosage form. Initial solubility alone is not enough to rank candidates. The study should also examine precipitation after dilution, maintenance of supersaturation, chemical stability, viscosity, particle size, dissolution, and interactions with other formulation components. The preferred system usually provides a practical balance among solubility improvement, stability, processability, and dosage-form compatibility.
Useful starting information includes the API structure, salt or free form, crystal form, solubility, pKa, hygroscopicity, known degradation pathways, available material quantity, and existing analytical methods. The intended dosage form, administration route, target drug loading, processing steps, storage conditions, and required functional properties should also be described. Candidate excipients, expected use levels, preliminary formulations, and unsuccessful experiments provide additional context. BOC Sciences uses these inputs to identify molecular and process risks, select functionally relevant excipients, define controls and mixture ratios, choose stress conditions and analytical endpoints, and adjust the screening scale to the available material.
BOC Sciences can provide agreed experimental conditions, analytical data, candidate comparisons, a multi-attribute ranking matrix, and an interpretation of important compatibility and performance signals. The report distinguishes confirmed incompatibilities from findings that require further investigation and conditions in which no meaningful risk was observed. It can explain how each excipient affected solubility, stability, dispersion, processing behavior, aggregation, or drug release. Recommendations may include prioritized excipients, practical concentration ranges, combinations to avoid, potential mitigation strategies, and proposed next experiments for multicomponent formulation confirmation, concentration optimization, or focused stability assessment.
BOC Sciences provided a clear ranking of compatible and incompatible excipients for our oral formulation. The thermal and chromatographic data made it easy for our team to select a safe matrix and avoid downstream stability problems.
— Dr. Johansson, Senior Formulation Scientist
We had very little API available, yet BOC Sciences designed a screening plan that used our material efficiently while still generating enough data to rank candidates. The project kept our limited supply and timeline in mind.
— Harrington, Preformulation Project Manager
The final report went beyond raw data. BOC Sciences gave us an actionable formulation recommendation with a rational excipient panel, which shortened our screening phase and moved us closer to a working prototype.
— Dr. Vance, Lead Development Chemist
BOC Sciences kept us updated at every stage, from candidate selection to compatibility testing and final recommendations. The transparent communication made the screening project easy to track and reduced uncertainty for our team.
— Mercer, Research Director, Formulation
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
